Sentigen Biosciences

Sentigen Biosciences was a biotechnology company specializing in the development of novel assay technologies for drug discovery, with a primary focus on G protein-coupled receptors (GPCRs). The company's proprietary Tango technology enabled the monitoring of GPCR activation in a cell-based format, facilitating high-throughput screening of potential drug candidates. Founded on research from the laboratory of Nobel laureate Richard Axel, Sentigen also explored the functional genomics of olfactory receptors to identify novel therapeutic targets. In 2006, the company was acquired by Invitrogen Corporation to enhance its portfolio of cell-based drug discovery tools and services. The Tango technology remains a significant component of the GPCR screening market under the Thermo Fisher Scientific brand.